Related Experiment Video
Updated: Jun 3, 2026

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived
Rainer Gosert1, Christine Hanssen Rinaldo, Marion Wernli
1Transplantation Virology, Institute for Medical Microbiology, Department of Biomedicine, University of Basel, and Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Petersplatz 10, CH-4003 Basel, Switzerland.
Abstract:
Polyomavirus JC (JCV) replication causes progressive multifocal leukoencephalopathy (PML), a frequently fatal brain disease in immunodeficient patients, yet antiviral drugs are lacking. We characterized the lipid conjugate 1-O-hexadecyloxypropyl-cidofovir (CMX001) regarding JCV (Mad-4) replication in human brain progenitor-derived astrocytes (PDA) and the simian virus 40 (SV40) large-T-antigen-expressing COS-7 cells up to 7 days postinfection (dpi). We examined JCV loads by PCR, the infection rate by immunofluorescence, and host cell toxicity by WST-1 and BrdU incorporation assays. Supernatants from CMX001-treated PDA demonstrated a drug concentration-dependent decrease in JCV loads and infectivity. CMX001 had only a modest effect on host cell metabolism but reduced overall BrdU incorporation. In PDA at 7 dpi, the CMX001 50% effective concentration (EC50) was 5.55 nM, the 50% cytotoxic concentration (CC50) was 184.6 nM, and the 50% selectivity index (SI50) was 33.3. The EC90 was 19.7 nM, the CC90 was 5,054 nM, and the SI90 was 256.1. In COS-7 cells, JCV replication was faster and the EC50 and EC90 were 18- and 37-fold higher than those in PDA, i.e., 0.1 μM and 0.74 μM (CC50, 0.67 μM; SI50, 6.7; CC90, 12.2 μM; SI90, 16.5) at 5 dpi. We conclude that CMX001 inhibits JCV replication at concentrations in vitro that can be attained by oral administration without significant side effects in clinical studies.
Insights
CMX001 effectively inhibits JC virus (JCV) replication in human brain cells, offering a potential treatment for progressive multifocal leukoencephalopathy (PML). This antiviral shows promise for patients with compromised immune systems.
Area of Science:
- Virology
- Neuroscience
- Pharmacology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a fatal brain disease caused by JC virus (JCV) replication.
- Immunodeficient patients are particularly susceptible to PML, and effective antiviral treatments are currently lacking.
Purpose of the Study:
- To characterize the antiviral activity of CMX001 against JCV replication in human brain progenitor-derived astrocytes (PDA) and COS-7 cells.
- To evaluate the efficacy and toxicity of CMX001 in vitro.
Main Methods:
- JCV replication was assessed using PCR and immunofluorescence assays.
- Host cell toxicity was determined by WST-1 and BrdU incorporation assays.
- Antiviral efficacy was quantified by calculating EC50, CC50, and SI50 values.
Main Results:
- CMX001 demonstrated a dose-dependent reduction in JCV loads and infectivity in PDA.
- CMX001 exhibited potent antiviral activity with low toxicity in PDA (SI50 = 33.3, SI90 = 256.1).
- JCV replication was inhibited by CMX001 at concentrations achievable through oral administration.
Conclusions:
- CMX001 is a potent inhibitor of JCV replication in vitro.
- CMX001 shows a favorable selectivity index, suggesting therapeutic potential for PML treatment.
- Further clinical studies are warranted to evaluate CMX001's efficacy and safety in patients.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Cytomegalovirus Disease
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Arboviral Encephalitis

